JOP20190241B1 - مستحضرات رذاذ إبينيفرين - Google Patents

مستحضرات رذاذ إبينيفرين

Info

Publication number
JOP20190241B1
JOP20190241B1 JOP/2019/0241A JOP20190241A JOP20190241B1 JO P20190241 B1 JOP20190241 B1 JO P20190241B1 JO P20190241 A JOP20190241 A JO P20190241A JO P20190241 B1 JOP20190241 B1 JO P20190241B1
Authority
JO
Jordan
Prior art keywords
spray formulations
epinephrine spray
epinephrine
present
directed
Prior art date
Application number
JOP/2019/0241A
Other languages
English (en)
Inventor
Rachana Inavolu
Craig Bastian
Thrimoorthy Potta
Chandeshwari Chilampalli
Venkat Goskonda
Eshwaran Narayanan
Ningxin Yan
Original Assignee
Hikma Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/488,712 external-priority patent/US10039710B2/en
Application filed by Hikma Pharmaceuticals Usa Inc filed Critical Hikma Pharmaceuticals Usa Inc
Publication of JOP20190241A1 publication Critical patent/JOP20190241A1/ar
Application granted granted Critical
Publication of JOP20190241B1 publication Critical patent/JOP20190241B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

غير متوفر
JOP/2019/0241A 2017-04-17 2018-04-17 مستحضرات رذاذ إبينيفرين JOP20190241B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/488,712 US10039710B2 (en) 2015-09-18 2017-04-17 Epinephrine spray formulations
PCT/US2018/027889 WO2018195029A1 (en) 2017-04-17 2018-04-17 Epinephrine spray formulations

Publications (2)

Publication Number Publication Date
JOP20190241A1 JOP20190241A1 (ar) 2019-10-09
JOP20190241B1 true JOP20190241B1 (ar) 2023-09-17

Family

ID=63857024

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0241A JOP20190241B1 (ar) 2017-04-17 2018-04-17 مستحضرات رذاذ إبينيفرين

Country Status (7)

Country Link
EP (1) EP3612173B1 (ar)
JP (1) JP2020516688A (ar)
CN (1) CN111050760A (ar)
CA (1) CA3060078A1 (ar)
ES (1) ES2960528T3 (ar)
JO (1) JOP20190241B1 (ar)
WO (1) WO2018195029A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
CA3178769A1 (en) 2020-05-18 2021-11-25 Jonas Savmarker New pharmaceutical composition for drug delivery
CN113750046B (zh) * 2021-10-27 2022-11-01 中国药科大学 一种用于过敏性休克的肾上腺素舌下喷雾剂及其制备方法和应用
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705942A (en) * 1969-09-29 1972-12-12 Ciba Geigy Corp Treatment of glaucoma employing imipramine or desmethylimipramine
DE69901936T2 (de) * 1998-01-30 2002-11-28 Novartis Consumer Health Sa Nasale lösungen
PT1531794T (pt) * 2002-06-28 2017-09-14 Civitas Therapeutics Inc Epinefrina inalável
US20140162965A1 (en) * 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20070059361A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
MX2011012735A (es) * 2009-06-04 2012-02-28 Alk Ag Composicion estabilizada que comprende por lo menos un compuesto adrenergico.
US8628805B2 (en) 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound
US20120322884A1 (en) 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
US20150246009A1 (en) * 2012-10-08 2015-09-03 Wockhardt Limited Stable injectable pharmaceutical composition of epinephrine or salts thereof
US20150374832A1 (en) * 2013-02-12 2015-12-31 Ys Pharm Tech Epinephrine formulations for medicinal products
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US20170079907A1 (en) * 2015-09-18 2017-03-23 Insys Development Company, Inc. Sublingual Epinephrine Spray

Also Published As

Publication number Publication date
EP3612173A4 (en) 2021-01-06
ES2960528T3 (es) 2024-03-05
EP3612173A1 (en) 2020-02-26
WO2018195029A1 (en) 2018-10-25
EP3612173B1 (en) 2023-10-11
CA3060078A1 (en) 2018-10-25
JP2020516688A (ja) 2020-06-11
CN111050760A (zh) 2020-04-21
JOP20190241A1 (ar) 2019-10-09

Similar Documents

Publication Publication Date Title
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
EA201790737A1 (ru) Комбинированная терапия
PH12017502103A1 (en) Methods and kits for treating depression
EA201790273A1 (ru) Флагеллиновые композиции и их применение
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
ZA202002779B (en) Dantrolene prodrugs and methods of their use
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
PH12019500725A1 (en) Methods of treating acute kidney injury
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
MX2017002388A (es) Composiciones para fibras de queratina.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2022015456A (es) Composiciones de maca y metodos de uso.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2020002147A (es) Composiciones útiles para la mejora del dolor.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
MX2016008272A (es) Metodos para el tratamiento de mujeres con trastornos de deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion bupropion y trazodona.
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen